Tumor-Elicited Inflammation and Colorectal Cancer

Advances in Cancer Research

Volumn 128, Issue , 2015, Pages 173-196

  Wang, Kepeng ^a   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colorectal cancer; IL 10; IL 17; IL 21; IL 22; IL 23; IL 6; Inflammation; TGF ; TNF

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CYTOKINE;

ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE COURSE; IMMUNOLOGY; PATHOLOGY; TUMOR MICROENVIRONMENT; CANCER GROWTH; COLITIS; DISEASE ASSOCIATION; MICROFLORA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; TUMOR MICROENVIRONMENT;

EID: 84952715663     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.04.014     Document Type: Chapter

References (137)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: A double-edged sword. Nature Reviews. Immunology 2003, 3:745-756.
2. Akhurst R.J., Derynck R. TGF-beta signaling in cancer-A double-edged sword. Trends in Cell Biology 2001, 11:S44-S51.
3. Algire G.H., Legallais F.Y., Anderson B.F. Vascular reactions of normal and malignant tissues in vivo. V. The role of hypotension in the action of a bacterial polysaccharide on tumors. Journal of the National Cancer Institute 1952, 12:1279-1295.
4. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England Journal of Medicine 2004, 350:2343-2351.
5. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. The Journal of Biological Chemistry 2002, 277:27613-27621.
6. Arnott C.H., Scott K.A., Moore R.J., Robinson S.C., Thompson R.G., Balkwill F.R. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2004, 23:1902-1910.
7. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647.
8. Backert I., Koralov S.B., Wirtz S., Kitowski V., Billmeier U., Martini E., et al. STAT3 activation in Th17 and Th22 cells controls IL-22-mediated epithelial host defense during infectious colitis. Journal of Immunology 2014, 193:3779-3791.
9. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Reviews 2006, 25:409-416.
10. Baltgalvis K.A., Berger F.G., Pena M.M., Davis J.M., Muga S.J., Carson J.A. Interleukin-6 and cachexia in ApcMin/+ mice. American Journal of Physiology, Regulatory, Integrative and Comparative Physiology 2008, 294:R393-R401.
11. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
12. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. The Journal of Clinical Investigation 1996, 98:1010-1020.
13. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
14. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
15. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
16. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
17. Burakoff R., Barish C.F., Riff D., Pruitt R., Chey W.Y., Farraye F.A., et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflammatory Bowel Diseases 2006, 12:558-565.
18. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
19. Cao A.T., Yao S., Gong B., Nurieva R.I., Elson C.O., Cong Y. Interleukin (IL)-21 promotes intestinal IgA response to microbiota. Mucosal Immunology 2015, [Epub ahead of print]. 10.1038/mi.2014.134.
20. Carmody R.J., Ruan Q., Liou H.C., Chen Y.H. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. Journal of Immunology (Baltimore, Md.: 1950) 2007, 178:186-191.
21. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the United States of America 1975, 72:3666-3670.
22. Chae W.J., Bothwell A.L. IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. Biochemical and Biophysical Research Communications 2011, 414:31-36.
23. Chae W.J., Gibson T.F., Zelterman D., Hao L., Henegariu O., Bothwell A.L. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:5540-5544.
24. Chen W.S., Liu J.H., Wei S.J., Liu J.M., Hong C.Y., Yang W.K. Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Science 2003, 94:253-258.
25. Chung A.Y., Li Q., Blair S.J., De Jesus M., Dennis K.L., LeVea C., et al. Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. Cancer Research 2014, 74:5377-5385.
26. Cottone M., Orlando A., Renna S. Investigational agents for Crohn's disease. Expert Opinion on Investigational Drugs 2010, 19:1147-1159.
27. Cua D.J., Tato C.M. Innate IL-17-producing cells: The sentinels of the immune system. Nature reviews Immunology 2010, 10:479-489.
28. Davidson N.J., Leach M.W., Fort M.M., Thompson-Snipes L., Kuhn R., Muller W., et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. The Journal of Experimental Medicine 1996, 184:241-251.
29. Dennis K.L., Wang Y., Blatner N.R., Wang S., Saadalla A., Trudeau E., et al. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Research 2013, 73:5905-5913.
30. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nature Genetics 2001, 29:117-129.
31. Dumoutier L., Lejeune D., Colau D., Renauld J.C. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. Journal of Immunology 2001, 166:7090-7095.
32. Dungan L.S., Mills K.H. Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. Cytokine 2011, 56:126-132.
33. Erdman S.E., Poutahidis T., Tomczak M., Rogers A.B., Cormier K., Plank B., et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. The American Journal of Pathology 2003, 162:691-702.
34. Erdman S.E., Rao V.P., Poutahidis T., Ihrig M.M., Ge Z., Feng Y., et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Research 2003, 63:6042-6050.
35. Erdman S.E., Sohn J.J., Rao V.P., Nambiar P.R., Ge Z., Fox J.G., et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Research 2005, 65:3998-4004.
36. Feagins L.A., Souza R.F., Spechler S.J. Carcinogenesis in IBD: Potential targets for the prevention of colorectal cancer. Nature Reviews. Gastroenterology & Hepatology 2009, 6:297-305.
37. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews. Drug Discovery 2004, 3:391-400.
38. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology 1991, 147:3815-3822.
39. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. Journal of Immunology 1991, 146:3444-3451.
40. Gounaris E., Blatner N.R., Dennis K., Magnusson F., Gurish M.F., Strom T.B., et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Research 2009, 69:5490-5497.
41. Grady W.M., Myeroff L.L., Swinler S.E., Rajput A., Thiagalingam S., Lutterbaugh J.D., et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Research 1999, 59:320-324.
42. Grivennikov S.I. IL-11: A prominent pro-tumorigenic member of the IL-6 family. Cancer Cell 2013, 24:145-147.
43. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
44. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
45. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
46. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature immunology 2005, 6:1123-1132.
47. Harrison C. Cancer: IL-22: Linking inflammation and cancer. Nature Reviews. Drug Discovery 2013, 12:504.
48. He D., Li H., Yusuf N., Elmets C.A., Athar M., Katiyar S.K., et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PloS One 2012, 7:e32126.
49. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
50. Hilton D.J., Hilton A.A., Raicevic A., Rakar S., Harrison-Smith M., Gough N.M., et al. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. The EMBO Journal 1994, 13:4765-4775.
51. Hinoi T., Akyol A., Theisen B.K., Ferguson D.O., Greenson J.K., Williams B.O., et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Research 2007, 67:9721-9730.
52. Huber S., Gagliani N., Zenewicz L.A., Huber F.J., Bosurgi L., Hu B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
53. Huh J.R., Leung M.W., Huang P., Ryan D.A., Krout M.R., Malapaka R.R., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011, 472:486-490.
54. Huh J.R., Littman D.R. Small molecule inhibitors of RORgammat: Targeting Th17 cells and other applications. European Journal of Immunology 2012, 42:2232-2237.
55. Hyun Y.S., Han D.S., Lee A.R., Eun C.S., Youn J., Kim H.Y. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012, 33:931-936.
56. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34:149-162.
57. Jauch D., Martin M., Schiechl G., Kesselring R., Schlitt H.J., Geissler E.K., et al. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 2011, 60:1678-1686.
58. Kimelman D., Kirschner M. Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 1987, 51:869-877.
59. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. The Journal of Experimental Medicine 2013, 210:917-931.
60. Kishimoto T. IL-6: From its discovery to clinical applications. International Immunology 2010, 22:347-352.
61. Kitakata H., Nemoto-Sasaki Y., Takahashi Y., Kondo T., Mai M., Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Research 2002, 62:6682-6687.
62. Knight B., Yeoh G.C., Husk K.L., Ly T., Abraham L.J., Yu C., et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. The Journal of Experimental Medicine 2000, 192:1809-1818.
63. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
64. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer cell 2009, 15:114-123.
65. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. The Journal of Biological Chemistry 2001, 276:2725-2732.
66. Kryczek I., Lin Y., Nagarsheth N., Peng D., Zhao L., Zhao E., et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014, 40:772-784.
67. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World Journal of Gastroenterology 2008, 14:3937-3947.
68. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews. Molecular Cell Biology 2014, 15:178-196.
69. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
70. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. The Journal of experimental medicine 2005, 201:233-240.
71. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annual Review of Immunology 1998, 16:137-161.
72. Li Q., Han Y., Fei G., Guo Z., Ren T., Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunology Letters 2012, 148:144-150.
73. Lim C., Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine & Growth Factor Reviews 2014, 25:257-271.
74. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine & Growth Factor Reviews 1996, 7:93-102.
75. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
76. Massague J., Attisano L., Wrana J.L. The TGF-beta family and its composite receptors. Trends in Cell Biology 1994, 4:172-178.
77. Massague J., Chen Y.G. Controlling TGF-beta signaling. Genes & Development 2000, 14:627-644.
78. McAllister F., Bailey J.M., Alsina J., Nirschl C.J., Sharma R., Fan H., et al. Oncogenic kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 2014, 25:621-637.
79. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews. Drug Discovery 2012, 11:763-776.
80. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nature Medicine 1999, 5:828-831.
81. Moser A.R., Mattes E.M., Dove W.F., Lindstrom M.J., Haag J.D., Gould M.N. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:8977-8981.
82. Moses H.L., Yang E.Y., Pietenpol J.A. TGF-beta stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 1990, 63:245-247.
83. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
84. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
85. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
86. Ozaki K., Kikly K., Michalovich D., Young P.R., Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:11439-11444.
87. Ozaki K., Spolski R., Ettinger R., Kim H.P., Wang G., Qi C.F., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of blimp-1 and Bcl-6. Journal of Immunology 2004, 173:5361-5371.
88. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
89. Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. Anti-TNF-alpha therapies: The next generation. Nature Reviews. Drug Discovery 2003, 2:736-746.
90. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology (Baltimore, Md.: 1950) 2002, 168:5699-5708.
91. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature immunology 2005, 6:1133-1141.
92. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
93. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban J.F., Cheever A.W., et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. The Journal of Clinical Investigation 2006, 116:2044-2055.
94. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. The Journal of Clinical Investigation 2008, 118:560-570.
95. Putoczki T.L., Thiem S., Loving A., Busuttil R.A., Wilson N.J., Ziegler P.K., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
96. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
97. Reynolds J.M., Angkasekwinai P., Dong C. IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine & Growth Factor Reviews 2010, 21:413-423.
98. Rosenberg D.W., Giardina C., Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009, 30:183-196.
99. Roses R.E., Xu S., Xu M., Koldovsky U., Koski G., Czerniecki B.J. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. Journal of Immunology (Baltimore, Md.: 1950) 2008, 181:5120-5127.
100. Rustgi A.K. The genetics of hereditary colon cancer. Genes & Development 2007, 21:2525-2538.
101. Sabat R., Ouyang W., Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nature Reviews. Drug Discovery 2014, 13:21-38.
102. Salcedo R., Worschech A., Cardone M., Jones Y., Gyulai Z., Dai R.M., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: Role of interleukin 18. The Journal of Experimental Medicine 2010, 207:1625-1636.
103. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
104. Schetter A.J., Nguyen G.H., Bowman E.D., Mathe E.A., Yuen S.T., Hawkes J.E. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:5878-5887.
105. Shattuck-Brandt R.L., Varilek G.W., Radhika A., Yang F., Washington M.K., DuBois R.N. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000, 118:337-345.
106. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014, 64:104-117.
107. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014, 64:9-29.
108. Solt L.A., Kumar N., Nuhant P., Wang Y., Lauer J.L., Liu J., et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472:491-494.
109. Stolfi C., Rizzo A., Franze E., Rotondi A., Fantini M.C., Sarra M., et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. The Journal of Experimental Medicine 2011, 208:2279-2290.
110. Sutton C.E., Mielke L.A., Mills K.H. IL-17-producing gammadelta T cells and innate lymphoid cells. European Journal of Immunology 2012, 42:2221-2231.
111. Tanaka T., Kohno H., Suzuki R., Yamada Y., Sugie S., Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Science 2003, 94:965-973.
112. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature Reviews. Genetics 2009, 10:353-358.
113. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114. e2105.
114. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology 2003, 15:740-746.
115. Tong Z., Yang X.O., Yan H., Liu W., Niu X., Shi Y., et al. A protective role by interleukin-17F in colon tumorigenesis. PloS One 2012, 7:e34959.
116. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Research 2011, 71:1263-1271.
117. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity 2003, 19:641-644.
118. Van der Sluis M., De Koning B.A., De Bruijn A.C., Velcich A., Meijerink J.P., Van Goudoever J.B., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131:117-129.
119. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729.
120. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: Immunological playmakers. Nature immunology 2012, 13:722-728.
121. Wang C.Y., Eshleman J.R., Willson J.K., Markowitz S. Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Research 1995, 55:5101-5105.
122. Wang K., Kim M.K., Di Caro G., Wong J., Shalapour S., Wan J., et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014, 41:1052-1063.
123. Wang L., Yi T., Zhang W., Pardoll D.M., Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Research 2010, 70:10112-10120.
124. Williamson B.D., Carswell E.A., Rubin B.Y., Prendergast J.S., Old L.J. Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon. Proceedings of the National Academy of Sciences of the United States of America 1983, 80:5397-5401.
125. Wu T., Cui L., Liang Z., Liu C., Liu Y., Li J. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clinical Immunology 2013, 147:38-39.
126. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine 2009, 15:1016-1022.
127. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J., et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. The Journal of Biological Chemistry 2000, 275:31335-31339.
128. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Research 2009, 19:156-172.
129. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17F. The Journal of Experimental Medicine 2008, 205:1063-1075.
130. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology/Hematology 2001, 38:17-23.
131. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. The EMBO Journal 1999, 18:1280-1291.
132. Yin T., Taga T., Tsang M.L., Yasukawa K., Kishimoto T., Yang Y.C. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. Journal of Immunology 1993, 151:2555-2561.
133. Yu L.Z., Wang H.Y., Yang S.P., Yuan Z.P., Xu F.Y., Sun C., et al. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World Journal of Gastroenterology 2013, 19:2638-2649.
134. Zhang Q., Liu S., Ge D., Xue Y., Xiong Z., Abdel-Mageed A.B., et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Research 2012, 72:2589-2599.
135. Zhang Q., Liu S., Xiong Z., Wang A.R., Myers L., Melamed J., et al. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. The Prostate 2014, 74:869-879.
136. Zindl C.L., Lai J.F., Lee Y.K., Maynard C.L., Harbour S.N., Ouyang W., et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:12768-12773.
137. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nature Reviews. Immunology 2010, 10:248-256.